EUVIMEDEUVIMED entdecken
Crossref

Clinical determinants, diagnostic complexity, and molecular heterogeneity in NF1-associated and sporadic malignant peripheral nerve sheath tumors: A 25-year referral-center cohort

Clio Coste, Mehdi Brahmi, Franck Tirode, Armelle Dufresne, Isabelle Ray-Coquard, Marie Karanian, Nadège Corradini, Gualter Vaz, Marie-Pierre Sunyach, Patrick Combemale, Jean-Yves Blay, Mona Amini-Adle

European Journal of Cancer · 2026-09 · 245 · 116930

DOI: 10.1016/j.ejca.2026.116930 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2026-09. Verfasst von Clio Coste und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Centre Leon Berard, Lyon, France. Electronic address: clio.coste@lyon.unicancer.fr. Hauptthemen laut MEDLINE: Neurofibromatosis 1, Neurofibrosarcoma, Nerve Sheath Neoplasms. Die Arbeit nennt 42 Literaturangaben. Gefördert von: Laboratoire d'Excellence DEVweCAN, Centre Léon Bérard, National League Against Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Malignant peripheral nerve sheath tumors (MPNST) are rare, aggressive soft-tissue sarcomas frequently associated with neurofibromatosis type 1 (NF1). Prognostic factors and optimal treatment strategies remain poorly defined. METHODS: Retrospective cohort study including all MPNST patients managed at Centre Léon Bérard (2000-2025). Overall survival (OS) was estimated using Kaplan-Meier and multivariable Cox models with multiple imputation. Transcriptional heterogeneity was explored via bulk RNA sequencing in a tumor subset. RESULTS: The cohort comprised 206 patients and 219 tumor episodes. Median OS was 53.6 months. NF1-associated tumors had inferior OS compared with sporadic tumors (median OS 26.6 vs 141.0 months, p = 0.012), with a 5-year restricted mean survival time (RMST) reduction of 7.6 months (95% CI -13.8 to -1.2; p = 0.025). Independent predictors of worse OS were higher stage (HR 2.37, p < 0.001), FNCLCC grade (HR 1.79, p < 0.001), NF1 status (HR 1.74, p = 0.006), central location (HR 1.75, p = 0.013) and older age (HR 1.41 per 10 years, p < 0.001); female sex was protective (HR 0.46, p < 0.001). Major biopsy-surgical histologic discordance occurred in 21.3% of cases. Radiotherapy showed context-dependent survival associations, with benefit in grade 3 tumors (HR 0.39, p < 0.001), locally advanced disease (HR 0.32, p = 0.003) and after macroscopically incomplete resections (HR 0.34, p = 0.027). Exploratory transcriptomic analysis identified two NF1-independent expression states defined by Schwann-lineage/immune versus proliferative programs. CONCLUSIONS: Outcomes remain poor, particularly in NF1. Discordance supports centralized expert review. Disease extent and anatomical location are major prognostic drivers. Radiotherapy may be beneficial in selected high-risk contexts. The transcriptomic landscape supports hypothesis-generating biomarker development based on tumor-state biology beyond NF1 status alone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neurofibromatosis 1NeurofibrosarcomaNerve Sheath NeoplasmsHumansFemaleMaleRetrospective StudiesMiddle AgedAdultPrognosisAgedAdolescentYoung Adult

Stichwörter der Autor:innen

MPNSTMalignant peripheral nerve sheath tumorNF1Neurofibromatosis type 1Prognostic factorsRadiotherapySoft tissue sarcomaSurvival analysis

Autor:innen und Institutionen

  • Department of Medical Oncology, Centre Leon Berard, Lyon, France. Electronic address: clio.coste@lyon.unicancer.fr.
  • Department of Medical Oncology, Centre Leon Berard, Lyon, France; Centre de recherche en cancérologie de Lyon, INSERM U1052 - CNRS UMR5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, Lyon, France.
  • Centre de recherche en cancérologie de Lyon, INSERM U1052 - CNRS UMR5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, Lyon, France.
  • Department of Medical Oncology, Centre Leon Berard, Lyon, France.
  • Centre de recherche en cancérologie de Lyon, INSERM U1052 - CNRS UMR5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, Lyon, France; Biopathology Department, Centre Léon Bérard, Lyon, France.
  • Department of Paediatric Oncology, Institute for Paediatric Haematology and Oncology, Centre Léon Bérard, Lyon, France.

Förderung

  • Laboratoire d'Excellence DEVweCAN
  • Centre Léon Bérard
  • National League Against Cancer
  • European Network for Rare Adult Solid Cancers

Zitieren

APA

Coste, C., Brahmi, M., Tirode, F., Dufresne, A., Ray-Coquard, I., Karanian, M., Corradini, N., Vaz, G., Sunyach, M. P., Combemale, P., Blay, J. Y., & Amini-Adle, M. (2026). Clinical determinants, diagnostic complexity, and molecular heterogeneity in NF1-associated and sporadic malignant peripheral nerve sheath tumors: A 25-year referral-center cohort. European Journal of Cancer, 245, 116930. https://doi.org/10.1016/j.ejca.2026.116930

Vancouver

Coste C, Brahmi M, Tirode F, Dufresne A, Ray-Coquard I, Karanian M, et al. Clinical determinants, diagnostic complexity, and molecular heterogeneity in NF1-associated and sporadic malignant peripheral nerve sheath tumors: A 25-year referral-center cohort. European Journal of Cancer. 2026;245:116930. doi:10.1016/j.ejca.2026.116930

BibTeX
@article{Coste2026,
  author = {Coste, Clio and Brahmi, Mehdi and Tirode, Franck and Dufresne, Armelle and Ray-Coquard, Isabelle and Karanian, Marie and Corradini, Nadège and Vaz, Gualter and Sunyach, Marie-Pierre and Combemale, Patrick and Blay, Jean-Yves and Amini-Adle, Mona},
  title = {Clinical determinants, diagnostic complexity, and molecular heterogeneity in NF1-associated and sporadic malignant peripheral nerve sheath tumors: A 25-year referral-center cohort},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {245},
  pages = {116930},
  doi = {10.1016/j.ejca.2026.116930}
}
Kostenlos starten →